The Effects of Lyophilization on the Physico-Chemical Stability of Sirolimus Liposomes by Parvin Zakeri-Milani et al.
 
 
Advanced Pharmaceutical Bulletin, 2013, 3(1), 25-29 
doi: http://dx.doi.org/10.5681/apb.2013.005 
http://apb.tbzmed.ac.ir/ 
 
*Corresponding author: Parvin Zakeri-Milani, Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, 
Iran. 51664. Tel: +98 (411) 3392593, Fax: +98 (411) 3344798, E-mail: pzakeri @tbzmed.ac.ir 
 
 
 
Copyright © 2013 by Tabriz University of Medical Sciences 
The  Effects  of  Lyophilization  on  the  Physico-Chemical  Stability  of 
Sirolimus Liposomes 
Saeed Ghanbarzadeh
1,2, Hadi Valizadeh
3, Parvin Zakeri-Milani
4* 
1 Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. 
2 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. 
3 Research Center for Pharmaceutical Nanotechnology and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. 
4 Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Sirolimus  (Rapamycin,  SRL,  Rapamune,  C51H79NO13, 
CAS  No:  53123-88-9),  a  carbocyclic  lactone-lactam 
macrolide  antibiotic,  is  anatural  fermentation  product 
of the streptomyces hygroscopicus discovered in Rapa 
Nui  (Easter  Island).  Although  initially  isolated  as  an 
antifungal  agent  with  potent  anticandida  activity, 
subsequent studies revealed impressive antitumor  and 
immunosuppressive  activities.  It  binds  to  the 
immunophilin FKBP12 and interferes with the function 
of mTOR, thus blocking the progression from G1 to the 
S phase of the cell cycle and blockage of the response 
of  T  and  B  cells  to  cytokines  and  consequently  cell 
proliferation.  Although  SRL  and  Tacrolimus  are 
structural analogs, they have different mechanisms of 
action. Sirolimus is available in oral solution and tablet 
form.  It  is  rapidly  but  poorly  absorbed  after  oral 
administration  with  an  estimated  bioavailability  of 
15%.
1-8 
Liposomes are artificial vesicles, composed of lipidic 
amphiphiles,  usually  phospholipids,  which  organize 
themselves  in  water  to  form  an  aqueous  core 
surrounded by a lipidic bilayer. This structure allows 
liposomes to transport both hydrophilic and lipophilic 
compounds and have led to their clinical use as drug 
carriers  of  several  drug  classes  including  antibiotics, 
antifungals  and  anticancer  agents.  Liposomes  have  a 
50-year  history  of  use  with  numerous  applications. 
Their utility has included toxicity buffering of drugs, 
targeting to specific tissue sites, enhancement of drug 
efficacy or potency, dissolution of insoluble drugs and 
sustained release of drugs.
9-16 
However, its potential application as therapeutic agent 
is  still  challenged  by  its  physical  and  chemical 
instabilities in aqueous dispersions (e.g., hydrolysis and 
oxidation of phospholipids, encapsulated solute leakage 
and  liposome  aggregation)  for  long-term  storage. 
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Purpose: The major limitation in the widespread use of liposome drug delivery system 
is its instability. Lyophilization is a promising approach to ensure the long-term stability 
of liposomes. The aim of this study was to prepare sirolimus-loaded liposomes, study 
their stability and investigate the effect of lyophilization either in the presence or in the 
absence of lyoprotectant on liposome properties. Methods: Two types of multi-lamellar 
liposomes, conventional and fusogenic, containing sirolimus were prepared by modified 
thin  film  hydration  method  with  different  ratio  of  dipalmitoylphosphatidylcholine 
(DPPC), cholesterol and dioleoylphosphoethanolamine (DOPE), and were lyophilized 
with  or  without  dextrose  as  lyoprotectant.  Chemical  stability  investigation  was 
performed at 4°C and 25°C until 6 months using a validated HPLC method. Physical 
stability  was  studied  with  determination  of  particle  size  (PS)  and  encapsulation 
efficiency (EE %) of formulations through 6 months. Results: Chemical stability test at 
4°C and 25°C until 6 months showed that drug content of liposomes decreased 8.4% and 
20.2% respectively. Initial mean EE % and PS were 72.8 % and 582 nm respectively. 
After 6 months mean EE % for suspended form, lyophilized without lyoprotectant and 
lyophilized with lyoprotectant were 54.8 %, 62.3% and 67.1 % at 4°C and 48.2%, 60.4 
% and 66.8 % at 25°C respectively. Corresponding data for mean PS were 8229 nm, 
2397 nm and 688nm at 4°C and 9362 nm, 1944 nm and 737 nm at 25°C respectively. 
Conclusion: It is concluded that lyophilization with and without dextrose could increase 
shelf life of liposome and dextrose has lyoprotectant effect that stabilized liposomes in 
the lyophilization process.  
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Liposome  dispersions  prepared  from  commercially 
available lipids do not meet the required standards for 
long-term  stability  of  pharmaceutical  preparations.  If 
they are stored as aqueous dispersions the encapsulated 
drugs tend to leak out of the bilayer structureand the 
liposomes might aggregate or fuse on storage and it is 
generally  necessary  to  use  them  within  the  first  few 
months  of  preparation.  Accordingly,  many  methods 
available  for  stabilization  of  liposome  have  been 
investigated,  such  as  lyophilization,  freezing,  spray-
drying and supercritical fluid technology. Among these, 
lyophilization is the main approach used toextend the 
shelf-life  of  liposomes,  especially  for  liposome 
containing  thermo-sensitive  drugs.  Some  liposomal 
products in the market or in clinical trials are provided 
as a lyophilized powder.
17-21 
A  variety  of  sugars,  including  sucrose,  glucose, 
fructose,  maltose,  arabinose  and  trehalose  have  been 
shown  to  act  as  lyoprotectant  during 
dehydration/rehydration of liposomes.
22-26 
In  the  present  study,  SRL-entrapped  multilamellar 
liposomes were prepared using the thin film hydration 
method.  Physical  stability  tests  of  liposomal 
formulations of SRL were performed at 4°C and 25°C. 
Moreover the prepared liposomes were lyophilized to 
study  the  effect  of  lyophilization  with  and  without 
lyoprotectant and also to investigate the lyoprotectant 
effect to protect liposomes against fusion and leakage 
during storage at the same temperatures. 
 
Materials and Methods 
Materials 
Sirolimus  was  obtained  from  Poli  Company  (Lazio, 
Italy).  Dipalmitoylphosphatidylcholine  (DPPC)  and 
dioleoylphosphoethanolamine (DOPE) were purchased 
from  Lipoid  GMBH  (Ludwigshafen,  Germany). 
Cholesterol (Chol) was obtained from Merck Company 
(Darmstadt, Germany). All solvents were HPLC grade 
and  all  reagents  were  of  analytical  grade  and  were 
purchased  from  Merck  Company  (Darmstadt, 
Germany).  
 
Liposome preparation 
SRL  multilamellar  liposomal  formulations  with 
different molar ratios were prepared using the thin film 
hydration technique. The lipid components (DPPC and 
Chol) either alone or mixed with DOPE, in the case of 
fusogenic  liposome,  with  different  molar  ratios  were 
dissolved in chloroform:methanol mixture (3:1, % v/v) 
in a round-bottomed flask. The organic solvents were 
slowly removed under reduced pressure, using a rotary 
evaporator  (Buchi,  Zurich,  Switzerland),  at  45°C, 
above gel-liquid crystal transition temperature (Tc) of 
phospholipids, such that a very thin film of dry lipids 
was formed on the inner surface of the flask. The dry 
lipid film was slowly hydrated with 20 ml of phosphate 
buffered saline (PBS) (pH 7.4) containing SRL 500 µg/ 
ml for 3 hrs in rotary leading to the formation of multi-
lamellar  liposomes.  The  resulting  suspension  was 
sonicated for 10 min to reduce liposome size. 
 
Chemical stability of SRL 
Samples of liposomal formulations in suspension and 
lyophilized  form  in  4°C  and  25°C  were  investigated 
initially and monthly until 6 months using previously 
developed HPLC method.
27 
 
Lyophilization  of  liposomes  and  subsequent 
reconstitution  
The  lyoprotectant  (dextrose)  was  dissolved  in 
phosphate  buffered  saline  at  concentration  of  10%. 
Liposomal  suspensions  in  buffer  with  or  without 
lyoprotectant  were  freeze-dried  (ZIRBUS  sublimator 
400,  ZIRBUS  Technology,  Bad  Grund,  Germany) 
where the liquid was frozen at-195°C. Dehydration step 
lasted for 2 days at temperature of  -40°C until  dried 
powder formed. The resulting lyophilized powderswere 
rehydrated to its original volume at room temperature 
with  PBS,  and  following  the  addition  of  PBS  the 
samples were equilibrated at room temperature for 30 
min. Then the samples were subjected to the following 
tests. 
 
Physical stability of liposomal formulations 
Storage  stability  of  all  suspensions  and  lyophilized 
formulations  was  tested  at  4°C  and  25°C  for  six 
months. 
 
Determination  of  drug  content  and  encapsulation 
efficiency (EE %) of liposomes  
Unentrapped drug was separated using dialysis method 
at  temperature  below  gel-liquid-crystalline  transition 
temperature (Tc) in sink condition after 24 hrs. Drug 
content  in  the  liposome  dispersion  and  unentrapped 
drug were analyzed with RP-HPLC system (Beckman, 
USA).  The  as  follow:  Knauer  C18  column 
(4.6×150mm,  5µm)  (Berlin,  Germany)  was  used  at 
54°C,  mobile  phase  consisting  of  acetonitril  and 
ammonium acetate buffer (pH5.8)(70:30, % v/v) with 
flow rate of 1.5 ml/min, detection wavelength was set 
at  278  nm  and  injection  volume  was150µl.  A  linear 
response was observed over a concentration range of 
125–2000  ng/ml  (r
2>  0.991).  For  all  quality  control 
(QC) standards in intraday and interday assay, accuracy 
and  precision  ranges  were  0.96  to  6.30  and  0.86  to 
13.74  respectively,  demonstrating  the  acceptable 
precision and accuracy over the analytical range. 
EE %was calculated by the following equation:
28-32 
EE (%) = [(C total –C free)/C total] ×100 
Where  C  total  is  total  drug  concentration  which  was 
added  and  C  free is  the  concentration  of  unentrapped 
drug. 
 
Measurement of particle size distribution of liposome 
Mean  vesicle  size  and  size  distribution  profile  of 
liposome was determined  using particle size  analyzer  
|    27 
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(Shimadzu, Japan) which uses laser diffraction method. 
All sample measurements were conducted in triplicate. 
 
Results and Discussion 
Chemical stability of SRL 
After six months storage at 4°C and 25°C, drug content 
of  liposomes  following  disruption  of  liposome  in 
methanol and after enough dilution was analyzed with 
RP-HPLC method. Results revealed that SRL content 
of liposomes after 6 months was 91.6 ± 2.3% at 4°C 
and  79.8  ±3.6%  at  25°C  for  suspended  form. 
Respective results for lyophilized form at the end of 6 
months  storage  were  92.3  ±1.6%  and  81.6±2.7% 
(Figure  1).  Therefore  it  can  be  concluded  that 
hydrolysis has small effect in SRL degradation. 
 
 
Figure 1. Chemical stability of SRL during 6 months in the 
suspension and lyophilized form 
 
Physical stability studies 
Physical  stability  study  of  SRL  liposomes  was 
conducted  at  refrigeration  temperature  (4°C)  and  at 
room  temperature  (25°C)  for  a  period  of  6  months. 
Drug  entrapment  of  liposomes  in  suspension  and 
reconstituted  liposome  was  evaluated  monthly.  The 
results  are  demonstrated  in  Figure  2  in  terms  of 
percentage of SRL retained in the liposomes.  
 
 
Figure 2. Mean EE % of different forms of multilamellar SRL 
liposomes stored at 4°C and 25°C 
 
Mean  initial  EE  %  for  liposomes  was  72.8  %  and 
average  retained  SRL  percent  in  liposomal 
formulations after 6 months were 54.8 %, 62.3 % and 
67.1  %  for  suspended  form,  lyophilized  without 
lyoprotectant and lyophilized with dextrose (Lyo + D) 
respectively. The retained drug in formulations after 6 
months storage at 25°C was 48.2 %, 60.4 % and 66.8 % 
respectively (Figure 2). 
Lyophilization  increases  the  shelf-life  of  liposomal 
formulation  and  preserves  it  in  dried  form  as  a 
lyophilized cake to be reconstituted with water prior to 
administration.  To  maintain  the  same  particle  size 
distribution  after  lyophilization-  rehydration  cycle,  a 
lyoprotectant needs to be added. Since the process of 
lyophilization is harmful for the liposome integrity, an 
obvious decrease in the encapsulation efficiency is seen 
for lyophilized formulations. In fact freeze-drying leads 
to destroy the membrane function of the phospholipid 
bilayer. In the present study we have used dextrose as 
protecting agent.  It  is  well-known that  sugars  can  be 
applied to prevent aggregation of nanoparticles during 
drying and storage. A literature review reveals that in 
previous  studies  various  sugars  were  investigated  for 
their  ability  to  protect  liposomes  against  fusion  and 
leakage during lyophilization process. Glavas-Dodov et 
al, showed that particle size, EE % and release profile 
did  not  differ  significantly  after  lyophilization  with 
saccharose.
33 However, in this study dextrose showed 
protective  effect  for  SRL  liposomes.  This  protective 
ability can extend both prevention of vesicle fusion and 
retention of encapsulated drug within the liposome. The 
protective  effect  during  liposome  lyophilization  is 
mainly determined by the formulation factors, such as 
the nature of  the drug, the  lipid bilayer  composition, 
and  the  choice  of  lyoprotectants.  The  stabilization 
property of sugars has been explained by the particle 
isolation  theory,  water  replacement  hypothesis  and 
vitrification  theory.
34-38  Liposomes  with  lyoprotectant 
showed  better  stability,  as  indicated  by  higher  drug 
retention.  Suspended  form  liposomes  had  the  less 
stability.  Initial  mean  particle  size  of  liposomes  was 
582  nm,  which  after  6  months  storage  at  4°C  were 
increased  up  to  8229  nm,  2397  nm  and  688  nm  for 
suspended form, lyophilized without lyoprotectant and 
lyophilized  with  dextrose  respectively.  However  in 
storage  at  25°C  particle  sizes  were  increased  more 
significantly  up  to  9362  nm,  1944  nm  and  737  nm 
respectively  (Figure  3).  Considering  0.01  as 
significance  level,  only  difference  in  particle  sizefor 
formulation lyophilized with dextrose and stored at 4°C 
wasn’t  significant  (P=0.026)  and  in  all  other 
formulations differences were significant (P<0.005). 
As mentioned before more SRL retained in liposomes 
in  lyophilized  formulations  compared  to  suspension 
form,  but  with  using  dextrose  for  lyophilization  of 
multi-lamellar  liposomes,  EE  %  was  higher.  The 
leakage of entrapped SRL could be explained by the 
fact  that  in  the  suspension  form,  lyophilization  and 
rehydration  of  a  liposomal  suspension  can  result  in 
leakage  of  internal  aqueous  contents.  Whereas,  with 
using dextrose as a lyoprotectant and in the absence of  
 28    | 
Ghanbarzadeh et al. 
 
Advanced Pharmaceutical Bulletin, 2013, 3(1), 25-29  Copyright © 2013 by Tabriz University of Medical Sciences 
protective agent, the amount of entrapped SRL didn’t 
decrease significantly (P> 0.15). 
 
 
Figure 3. Mean particle size of different forms of multilamellar 
SRL liposomes stored at 4°C and 25°C. 
 
Conclusion 
Instabilities of liposomes during storage are a serious 
limiting factor for their applicability as drug delivery 
systems.  Lyophilization  is  a  commonly  used  drying 
technique  for  thermolabile  pharmaceuticals  and  also 
various studies have demonstrated that lyophilization is 
an effective way to overcome the instability problems 
of  liposomes  in  the  aqueous  state.  The  present  work 
focuses  on  physicochemical  characterization  of 
lyophilized  SRL  loaded  multi-lamellar  liposomes  and 
short-term storage stability studies of formulation. The 
process  of  lyophilization  is  often  used  to  prepare 
pharmaceutical  formulations  to  achieve  commercially 
practicable shelf life and easy handling (shipping and 
storage). It is important to have a product of a desirable 
quality and maintain physicochemical characteristics of 
formulation during storage. It was observed that there 
was no significant change in drug content at 4°C and 
25°C  storage  conditions  for  6  months  in  lyophilized 
liposomes with and  without dextrose as  lyoprotectant 
(P>015)  but  decreasing  drug  content  in  suspension 
forms was significant  at both 4°C  and 25°C  (P=0.009 
and  P=0.005  respectively).  Whereas  significant 
increase (P<0.005) in size were observed at the same 
temperatures  over  6  months  of  storage  in  all 
formulations  except  lyophilized  form  with 
lyoprotectant  (P=0.026).  Taken  together,  studies 
showed  superior  stability  of  the  lyophilized  product 
after  reconstitution  in  comparison  with  those  of  the 
suspension product,  and  physico-chemical  stability  of 
products which have dextrose was most superior. Then 
we could conclude that lyophilization with and without 
dextrose  could  increase  shelf  life  of  liposome  and 
glucose  has  lyoprotectant  effect  that  stabilized 
liposomes  in  the  lyophilization  process.  Overall, 
studies  on  the  optimization  of  formulation  and 
technological parameters to improve the lyoprotective 
effect  are  still  required  for  improving  liposome 
lyophilization. 
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